Navigation Links
Alexion Commences Dosing in AEGIS Registration Study of Soliris(R) (eculizumab) in Patients with PNH in Japan
Date:1/7/2008

apan the same innovative therapy that is already available to patients in the U.S. and Europe," said Dr. Yuzuru Kanakura, M.D. Ph.D., Professor and Chairman Department of Hematology and Oncology, Osaka University Graduate School of Medicine. "We are excited to be participating in such an important study and look forward to the Soliris program progressing to registration in Japan."

"After consultation with the leading PNH clinical investigators in Japan and with the PMDA, we are pleased to have commenced dosing with Soliris in the AEGIS study, our single Japanese registration trial," said Leonard Bell, M.D., Chief Executive Officer of Alexion. "After completing enrollment and dosing, and comparing these results in Japanese patients to our earlier PNH studies, we expect to submit a licensing application for Soliris in PNH to the Japanese regulatory authority. Initiating this Japanese registration study is an important component of reaching our global goal that every PNH patient who can benefit from Soliris will have access to it."

About PNH

PNH is a rare blood disease that affects an estimated 8,000 to 10,000 people in North America and Europe and, using similar prevalence estimates, potentially 1,000 - 2,000 patients in Japan. (3) PNH often strikes people in the prime of their lives, with an average age of onset in the early 30's. (4) Approximately ten percent of all patients first develop symptoms at 21 years of age or younger. (5) PNH develops without warning and can occur in men and women of all races, backgrounds and ages. PNH often goes unrecognized, with delays in diagnosis often ranging from one to more than 10 years. (6) The estimated median survival for PNH patients is between 10 and 15 years from the time of diagnosis. (4,6)

PNH has been identified more commonly among patients with disorders of the bone marrow, including aplastic anemia (AA) and myelodysplastic syndrome (MDS). (7,8,9,10) In patients with thrombosis of unknown ori
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Commences Phase 2 Study with MKC-1 in Pancreatic Cancer
2. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
3. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
4. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
5. Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine
6. Memory Pharmaceuticals Commences Phase 1 Clinical Program for R4996/MEM 63908
7. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. MDS Patients on Five-Day Vidaza(R) Dosing Schedules Achieve Transfusion Independence Consistent with Seven-day Schedule
11. VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ... the development and commercialization of novel bile acid therapeutics ... of an underwritten public offering of 1,730,000 shares of ... $33.01 per share.  In addition, Intercept has granted the ... additional 259,500 shares of common stock. All ...
(Date:6/18/2013)... Royal Philips (NYSE: PHG, AEX: ... Leader in Imaging Equipment in the 2013 Best in ... received Best in KLAS and Best in Category awards ... Computed Tomography (CT), Ingenia 1.5T and 3.0T Magnetic ... annual Best in KLAS Awards: Medical Imaging & Infrastructure ...
(Date:6/18/2013)... 18, 2013  Specialty Coating Systems is ... Parylene coating technologies: SCS microRESIST™ Antimicrobial Parylene ... Parylene with antimicrobial properties to effectively eliminate ... (Logo: http://photos.prnewswire.com/prnh/20130618/DE33772LOGO ) ... and continue to pose a challenge to ...
Breaking Medicine Technology:Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2Philips Named 2013 Overall Performance Leader In Imaging Equipment By KLAS 2Specialty Coating Systems Announces New Antimicrobial Parylene Technology 2
... July 30 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc.,(NYSE: ... China and the United States , today,announced that it will release financial results ... U.S. market opens. , , , ... (Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO ) , , ...
... July 30 Water Street Healthcare ... on health care, announced today that it has acquired ... Stoughton, Massachusetts , MSD is the nation,s leading ... solutions to the growing home infusion therapy market.  The ...
Cached Medicine Technology:WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call 2WuXi PharmaTech RESCHEDULES Second-Quarter 2010 Earnings Conference Call 3Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 2Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 3Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC 4
(Date:6/19/2013)... mantra of neurologists treating stroke victims has been "time equals ... quickly to receive a drug that dissolves the stroke-causing blood ... tissue is saved or lost. , But specific ... giving the intravenous drug known as a tissue plasminogen ... (clot-caused), stroke, the most common type of stroke. ...
(Date:6/19/2013)... cancer is many fold higher in persons over 65 ... on how best to treat these older cancer patients. ... clinical trials, those elderly patients who are eventually included ... elderly patient population is not well represented in clinical ... is now starting a new phase 2 trial in ...
(Date:6/19/2013)... Orlando, FL (PRWEB) June 19, 2013 Fit ... and Andrea Laing recently held a charity boot camp in ... cystic fibrosis. The fitness boot camp franchise hosted ... a.m. to 11 a.m. with 75 boot camp participants and ... June charity boot camp marks the second fundraiser held for ...
(Date:6/19/2013)... IL (PRWEB) June 19, 2013 A ... but for those closest to them. The sudden onset ... a brain tumor has on a patient’s behavioral and ... for both the patient and family. The American ... Friday, July 26 and Saturday, July 27 in Chicago, ...
(Date:6/19/2013)... When looking for ways to lose weight ... how to lose belly fat and excess fat in other ... Unnecessary and excess fat storage in these areas can be ... created their hCG diets to specially address these ... loss aids with nutritious meal plans and education on healthy ...
Breaking Medicine News(10 mins):Health News:Timely treatment after stroke is crucial, UCLA researchers report 2Health News:Timely treatment after stroke is crucial, UCLA researchers report 3Health News:EORTC study opens for elderly patients with HER-2 positive metastatic breast cancer 2Health News:Fit Body Boot Camp in Orlando Held Successful “Brent Can Breathe” Charity Boot Camp with Proceeds Going to Support Orlando Local Brent Snyder with Cystic Fibrosis 2Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 2Health News:American Brain Tumor Association Conference Advances Holistic Approach to Living with a Brain Tumor 3Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announce A New Four Phase Program that Allows Patients to Lose Belly Fat, Thigh Fat and Underarm Fat Easily 2
... ... of the RDX storage technology include industry leaders Dell, Fujitsu, Hitachi, HP, IBM, Imation, Maxell, ... ... announced that Maxell , a technology and marketing leader in premium data storage media ...
... Check City has ... completed applications as well as multiple tiers of sales commissions for funded loans through their ... of the highest affiliate commissions in the financial services industry. , ... Orem, UT (PRWEB) February 22, 2010 -- Check City, ...
... ... for millions of PowerPoint and Keynote users to up their game , ... Santa Clara, California (PRWEB) February ... SpeakFlow™, a suite of tools for creating, managing, and delivering non-linear presentations, immediately available ...
... ... new virtual reality device, the GaitAid, can help stroke patients learn to walk better. , ... Haifa, Israel (PRWEB) February 22, 2010 -- There ... is one of the leading causes of adult disability in the U.S. and Europe., , , ...
... has found that many male cancer survivors who develop ... an impaired quality of life and reduced energy levels. ... journal of the American Cancer Society, the study suggests ... benefit from testosterone replacement therapy. Testosterone deficiency is ...
... ... ... ... ...
Cached Medicine News:Health News:Maxell Joins RDX Storage Alliance to Support Growing Storage Professionals' Community 2Health News:Maxell Joins RDX Storage Alliance to Support Growing Storage Professionals' Community 3Health News:Check City Announces New Payday Affiliate Campaign Through Partnership With The Share A Sale Affiliate Network 2Health News:Check City Announces New Payday Affiliate Campaign Through Partnership With The Share A Sale Affiliate Network 3Health News:SharpLogic Announces Launch Of SpeakFlow Non-Linear Presentation Suite At SpeakFlow.com 2Health News:SharpLogic Announces Launch Of SpeakFlow Non-Linear Presentation Suite At SpeakFlow.com 3Health News:New Successful Treatment Improves Walking Post Stroke 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 2Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 3Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 4Health News:WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday 5
... of Sleepscan VISION ensures flexibility in system ... Sleepscan VISION utilizes the powerful Netlink amplifier ... a standard Ethernet connection. Only computer industry ... the Sleepscan VISION to take advantage of ...
... 25 years, Bio-logic has demonstrated continuous innovations ... introduced the first Digital EEG system brings ... you! Ceegraph VISION is the first Windows ... to integrate all your EEG needs: epilepsy ...
... From the Pioneer in Digital ... first Digital EEG system presents the ... - the Ceegraph VISION. This innovative ... networking, remote communications and information management ...
... When you purchase an XLTEK Mobee, you're getting ... one. Both the Mobee32 and the Mobee O2 ... PSG recording, traditional in-lab EEG monitoring, or in-lab ... that allow for full 10/20 electrode placement. The ...
Medicine Products: